Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
PARSIPPANY, N.J., Aug. 09, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 2017 Wedbush Pacgrow Healthcare Conference at 9:10 AM ET on Tuesday, August 15, 2017 in New York City.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
